Download in electronic PDF format for $75

Abstract:  The role of the compounding pharmacist is critical during the treatment of animals with cancer. In this article, the author discusses methods of therapy, considerations for extrapolation of therapies, chemoresponsive tumors (lymphoma, mast cell tumor, osteosarcoma, bladder cancer, postvaccinal sarcomas, equine tumors, sarcoids, squamous cell carcinoma and melanoma), specific intralesional and topical chemotherapy and immunotherapy, adverse sequelae to cancer treatment in animal patients, therapeutic options for pain in the cancer patient and frontiers of veterinary cancer therapy. She also provides tables with the following information: a chart showing conversion of body weight in kilograms to body surface area in meters squared for dogs, a chart showing conversion of body weight in kilograms to body surface area in meters squared for cats, compounded cancer treatment options for oral administration, considerations for extrapolation of human therapies to animal patients, a treatment protocol for canine lymphoma, a feline lymphoma treatment protocol, canine mast cell tumor treatment options, a canine osteosarcoma treatment protocol, a feline vaccine-associated sarcoma treatment protocol, equine sarcoid treatment options, equine squamous cell carcinoma treatment options, equine melanoma treatment options, compounded intralesional and topical chemotherapeutic agents, treatment options for adverse sequelae to cancer treatment and therapeutic options for pain management in the veterinary cancer patient.

Related Keywords: animal patients, animals, antineoplastic, bladder cancer, cancer, cat, chemotherapy, cytotoxic, dog, equine tumors, horse, immunotherapy, lyphoma, mast cell tumor, melanoma, oncolgists, osteosarcoma, pets, postvaccinal sarcomas, sarcoids, squamous cell carcinoma, veterinary

Related Categories: CANCER AND AIDS, VETERINARY

Printer-Friendly Version